Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeting c-Kit mutations: basic science to novel therapies.

Martin Sattler1, Ravi Salgia

  • 1Department of Medical Oncology, Dana-Farber Cancer Institute, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA 02115, USA.

Leukemia Research
|March 24, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dual CDK2 and CDK4/6 inhibition suppresses Rb/E2F signaling and enhances anti-leukemic activity in acute myeloid leukemia.

Haematologica·2026
Same author

The IMMUNO-BIOMAP trial in NSCLC: An adaptive multimodal framework for biomarker-guided care.

Cell reports. Medicine·2026
Same author

Diagnostic Challenges in Pleural Mesothelioma.

Cancers·2026
Same author

Editorial Expression of Concern: Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers.

Nature medicine·2026
Same author

YAP1 drives aggressive and therapy resistant state in melanoma through reprogramming the chromatin and regulating immune evasive programs.

bioRxiv : the preprint server for biology·2025
Same author

Erratum: Dual CARM1-and IKZF3-targeting: A novel approach to multiple myeloma therapy.

Molecular therapy. Oncology·2025

The Kit receptor tyrosine kinase (RTK) plays a key role in various cancers. Understanding its molecular mechanisms is crucial for developing new therapies and overcoming drug resistance in Kit-driven tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Signal Transduction

Background:

  • The Kit receptor tyrosine kinase (RTK) is crucial for normal development and is implicated in various malignancies.
  • Aberrant activation of the SCF/Kit pathway, through mutations or ligand-mediated mechanisms, drives tumor growth and metastasis.
  • Kit is frequently activated in gastrointestinal stromal tumors (GISTs) and lung cancers.

Purpose of the Study:

  • To review the molecular mechanisms underlying Kit-mediated cellular transformation.
  • To discuss the role and expression of Kit in different malignancies.
  • To highlight the importance of understanding Kit biology for developing novel therapeutic strategies.

Main Methods:

  • Literature review of studies on Kit receptor tyrosine kinase.

Related Experiment Videos

  • Analysis of molecular mechanisms involved in Kit-driven oncogenesis.
  • Examination of Kit expression and mutations in various cancers.

    • Main Results:

    • Kit activation enhances tumor growth and reduces apoptosis, contributing to metastasis.
    • Imatinib mesylate (Gleevec) shows efficacy in Kit-mutated GISTs.
    • Cancer chemotherapy resistance is a significant challenge, necessitating further research into Kit signaling pathways.

    Conclusions:

    • Understanding the molecular mechanisms of Kit transformation is essential for identifying new drug targets.
    • Targeting Kit-specific signaling pathways may overcome therapeutic resistance.
    • Further insights into c-Kit biology will lead to improved cancer therapeutics.